Form 4: Lexicon Pharmaceuticals Executive Brian Corrigan Acquires 200,000 Stock Options
SEC Form 4 Filing
Brian Corrigan, SVP of Regulatory & QA at Lexicon Pharmaceuticals, acquired 200,000 stock options on August 12, 2024.
Summary
- Brian Corrigan, SVP of Regulatory & QA at Lexicon Pharmaceuticals, filed a Form 4 on August 12, 2024.
- The filing reports a transaction involving derivative securities.
- Corrigan acquired 200,000 stock options with an exercise price of $1.60 on August 12, 2024.
- The options expire on August 12, 2034.
- The options vest over time, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports a transaction.
Positives
- The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor impact on shareholders, as it reflects an executive's investment in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of the transaction: Brian Corrigan acquired 200,000 stock options. |
| 08/12/2024 | Date of Form 4 filing. |
| 08/12/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.